Anti-TIGIT Antibody Dosing Regimen for Cancer Survival
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for efficacious immunotherapies and dosing methods for the treatment of cancer, particularly in addressing the significant societal burden of cancer mortality and morbidity.
Innovation Solution
The use of a dosing regimen comprising anti-TIGIT antagonist antibodies, PD-1 axis binding antagonists, platinum-based chemotherapeutic agents, and non-platinum-based chemotherapeutic agents, administered in specific doses and schedules, to treat cancer patients, including those with lung cancer, cervical cancer, and other types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional cancer treatments are used, then cancer can be treated, but progression-free survival and overall survival are limited
Solution Approach 1:
The patent combines anti-TIGIT antagonist antibody with PD-1 axis binding antagonist and chemotherapeutic agents into a multi-component treatment regimen. This combination approach synergistically enhances immune activation and tumor cell killing, extending progression-free survival and overall survival compared to single-agent therapies.
Solution Approach 2:
The treatment regimen functions as a composite therapeutic system integrating multiple mechanisms of action: TIGIT pathway inhibition, PD-1 pathway inhibition, and chemotherapeutic cytotoxicity. This composite approach addresses cancer through multiple simultaneous mechanisms, improving both durability of response and survival outcomes.
2Duration of action of stationary object
If conventional cancer treatments are used, then cancer can be treated, but overall survival is limited
Solution Approach 1:
The patent combines anti-TIGIT antagonist antibody with PD-1 axis binding antagonist and chemotherapeutic agents into a multi-component treatment regimen. This combination approach synergistically enhances immune activation and tumor cell killing, extending progression-free survival and overall survival compared to single-agent therapies.
Solution Approach 2:
The treatment regimen establishes continuous immune activation through dual pathway inhibition (TIGIT and PD-1), maintaining tumor-specific immune responses over extended periods. This continuous immunostimulation prevents disease progression and extends overall survival by sustaining anti-tumor immunity throughout the treatment course.
3Reliability
If immunotherapy alone is used, then treatment complexity is reduced, but treatment effectiveness is insufficient
Solution Approach 1:
The patent segments the treatment into distinct phases with specific dosing schedules: induction phase with multiple agents, followed by maintenance phase with reduced dosing frequency. This segmentation allows optimization of each treatment component's timing and dosage, maximizing effectiveness while managing complexity through structured administration.
Solution Approach 2:
The regimen employs parameter changes in dosing frequency and dosage levels between treatment phases. During the induction phase, higher doses are administered every 3 weeks, transitioning to maintenance phase with reduced dosing frequency every 4 weeks. These parameter adjustments optimize the balance between treatment effectiveness and manageable complexity.
Data Source
AI summary
The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a lung cancer; a cervical cancer; a breast cancer; a head and neck cancer; a liver cancer; a bladder cancer; a gastric cancer; an esophageal cancer; a pancreatic cancer; a kidney or renal cancer; a melanoma; an ovarian cancer; or a colorectal cancer). More specifically, the invention concerns the treatment of patients having cancer with an anti-TIGIT antagonist antibody, including treatment with an anti-TIGIT antagonist antibody in a combination therapy.